for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Illumina, Inc.

ILMN.OQ

Latest Trade

351.65USD

Change

4.37(+1.26%)

Volume

428,710

Today's Range

342.07

 - 

353.53

52 Week Range

335.68

 - 

555.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Illumina Reports Q3 NON-GAAP EPS Of $1.45

Nov 4 (Reuters) - Illumina Inc <ILMN.O>::ILLUMINA REPORTS FINANCIAL RESULTS FOR THIRD QUARTER OF FISCAL YEAR 2021.Q3 NON-GAAP EARNINGS PER SHARE $1.45.Q3 GAAP EARNINGS PER SHARE $2.08.Q3 REVENUE ROSE 40 PERCENT TO $1.108 BILLION.SEES 2021 GAAP EARNINGS PER SHARE $4.41 TO $4.51.SEES 2021 NON-GAAP EARNINGS PER SHARE $5.50 TO $5.60.Q3 EARNINGS PER SHARE VIEW $1.14, REVENUE VIEW $1.05 BILLION -- REFINITIV IBES DATA.FY2021 EARNINGS PER SHARE VIEW $5.73 -- REFINITIV IBES DATA.

Illumina Q2 Earnings Per Share $1.26

Aug 5 (Reuters) - Illumina Inc <ILMN.O>::ILLUMINA REPORTS FINANCIAL RESULTS FOR SECOND QUARTER OF FISCAL YEAR 2021.Q2 NON-GAAP EARNINGS PER SHARE $1.87.Q2 GAAP EARNINGS PER SHARE $1.26.Q2 REVENUE $1.126 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.02 BILLION.Q2 EARNINGS PER SHARE ESTIMATE $1.36 -- REFINITIV IBES DATA.RAISES FISCAL YEAR 2021 GUIDANCE.ILLUMINA - FOR FISCAL 2021, SEES Y-O-Y REVENUE GROWTH IN RANGE OF 32% TO 34%, GAAP EPS DILUTED OF $4.69 TO $4.89, NON-GAAP EPS DILUTED OF $6.30 TO $6.50.

Illumina Files Action For Annulment Of European Commission’S Decision Asserting Jurisdiction To Review Grail Acquisition

April 29 (Reuters) - Illumina Inc <ILMN.O>::ILLUMINA FILES ACTION FOR ANNULMENT OF EUROPEAN COMMISSION’S DECISION ASSERTING JURISDICTION TO REVIEW GRAIL ACQUISITION.ILLUMINA INC - COMMISSION ASSERTED JURISDICTION TO REVIEW ACQUISITION UNDER ARTICLE 22 OF EU MERGER REGULATION ON APRIL 19, 2021.

Illumina Reports Q1 Non GAAP EPS $1.89

April 27 (Reuters) - Illumina Inc <ILMN.O>::ILLUMINA REPORTS FINANCIAL RESULTS FOR FIRST QUARTER OF FISCAL YEAR 2021.Q1 NON-GAAP EARNINGS PER SHARE $1.89.Q1 GAAP EARNINGS PER SHARE $1.00.Q1 REVENUE ROSE 27 PERCENT TO $1.093 BILLION.Q1 EARNINGS PER SHARE VIEW $1.38, REVENUE VIEW $1.00 BILLION -- REFINITIV IBES DATA.FOR FISCAL 2021, EXPECTS YEAR-OVER-YEAR REVENUE GROWTH IN RANGE OF 25% TO 28%.EXPECTS FY GAAP EARNINGS PER DILUTED SHARE OF $4.72 TO $4.97.SEES FY NON-GAAP EARNINGS PER DILUTED SHARE OF $5.80 TO $6.05.FY2021 EARNINGS PER SHARE VIEW $5.51, REVENUE VIEW $4.02 BILLION -- REFINITIV IBES DATA.

Illumina Remains Committed To Grail Acquisition To Accelerate Access To Breakthrough Multi-Cancer Early Detection Blood Test

April 20 (Reuters) - Illumina Inc <ILMN.O>::ILLUMINA REMAINS COMMITTED TO GRAIL ACQUISITION TO ACCELERATE ACCESS TO BREAKTHROUGH MULTI-CANCER EARLY DETECTION BLOOD TEST.ILLUMINA INC - WILL CONTINUE TO WORK WITH DIRECTORATE-GENERAL TO BRING INVESTIGATION TO CONCLUSION.ILLUMINA INC - DISAGREES WITH EUROPEAN COMMISSION'S DIRECTORATE-GENERAL FOR COMPETITION'S DECISION TO REVIEW ILLUMINA'S ACQUISITION OF GRAIL.

Illumina Sees Q1 Revenue About $1.085 Billion

April 5 (Reuters) - Illumina Inc <ILMN.O>::ILLUMINA ANNOUNCES PRELIMINARY REVENUE FOR FIRST QUARTER FISCAL YEAR 2021.SEES Q1 REVENUE ABOUT $1.085 BILLION.EXPECTS YEAR-OVER-YEAR REVENUE GROWTH IN RANGE OF 25%-28% IN FY 2021.RAISING 2021 REVENUE GUIDANCE.

Illumina Committed To Pursuing GRAIL Acquisition

March 30 (Reuters) - Illumina Inc <ILMN.O>::ILLUMINA COMMITTED TO PURSUING GRAIL ACQUISITION TO ACCELERATE ACCESS TO BREAKTHROUGH MULTI-CANCER EARLY DETECTION BLOOD TEST.ILLUMINA INC - WILL OPPOSE FTC'S CHALLENGE TO ITS PREVIOUSLY ANNOUNCED ACQUISITION OF GRAIL.ILLUMINA INC - ILLUMINA WILL PURSUE ITS RIGHT TO PROCEED WITH TRANSACTION.ILLUMINA INC - INTENDS TO PURSUE ALL LEGAL OPTIONS IN ORDER TO COMPLETE ACQUISITION.

US Court Grants MGI's Motion To Amend In Suit Against Illumina

Feb 23 (Reuters) - Illumina Inc <ILMN.O>::MGI TECH CO - US COURT GRANTS MGI'S MOTION TO AMEND IN SUIT AGAINST ILLUMINA.MGI - U.S. COURT GRANTS MOTION FOR LEAVE TO AMEND TO ADD NEW INEQUITABLE CONDUCT DEFENSE OF PATENT INFRINGEMENT LAWSUIT THAT ILLUMINA FILED IN FEB. 2020.

Illumina Reports Financial Results For Fourth Quarter And Fiscal Year 2020

Feb 11 (Reuters) - Illumina Inc <ILMN.O>::ILLUMINA REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FISCAL YEAR 2020.Q4 NON-GAAP EARNINGS PER SHARE $1.22.Q4 GAAP EARNINGS PER SHARE $1.75.Q4 EARNINGS PER SHARE ESTIMATE $1.11 -- REFINITIV IBES DATA.Q4 REVENUE $953 MILLION VERSUS REFINITIV IBES ESTIMATE OF $903.9 MILLION.FOR FISCAL 2021, COMPANY EXPECTS YEAR-OVER-YEAR REVENUE GROWTH IN RANGE OF 17% TO 20%.FOR FISCAL 2021, EXPECTS GAAP EARNINGS PER DILUTED SHARE OF $4.76 TO $5.01 AND NON-GAAP EARNINGS PER DILUTED SHARE OF $5.10 TO $5.35.FY2021 EARNINGS PER SHARE VIEW $6.11, REVENUE VIEW $3.90 BILLION -- REFINITIV IBES DATA.

Myriad Genetics Forms Strategic Partnership With Illumina In Oncology

Jan 11 (Reuters) - Myriad Genetics Inc <MYGN.O>::MYRIAD GENETICS FORMS STRATEGIC PARTNERSHIP WITH ILLUMINA IN ONCOLOGY.COLLABORATION WITH ILLUMINA FOR ILLUMINA TO CREATE KIT-BASED VERSION OF MYCHOICE COMPANION DIAGNOSTIC TEST FOR INTERNATIONAL MARKETS.PARTNERSHIP CONSISTS OF AGREEMENT FOR ILLUMINA TO PROVIDE KIT-BASED VERSION OF MYCHOICE CDX TEST FOR INTERNATIONAL MARKETS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up